Lobe Sciences Ltd. (CSE: LOBE) has appointed Tracy L. Goeken, M.D., as Chief Medical Officer, effective October 19, 2026, as the clinical-stage biopharmaceutical company advances two key drug candidates. Dr. Goeken brings more than 20 years of clinical development and regulatory experience, including work on Phase 3 generalized anxiety disorder studies and Phase 1 sickle cell disease trials. The appointment arrives as Lobe prepares a U.S. Investigational New Drug application for L-130 and advances S-100 toward Phase 3 development. Investors may also note the company's concurrent engagement of a market-making firm to support trading liquidity.

Key Points

  • Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF | FWB: LOBE.F) is a clinical-stage biopharmaceutical company developing therapies for neurological conditions and rare diseases.
  • Dr. Tracy L. Goeken, M.D., appointed Chief Medical Officer effective October 19, 2026, most recently serving as CMO at Linical, a global clinical research organisation.
  • Lobe is preparing an IND application for L-130, its psilocin-based candidate for generalized anxiety disorder, and advancing S-100, its oral lipid formulation for sickle cell disease, toward Phase 3.
  • Investors will be watching progress on the IND submission for L-130 and advancement of S-100 toward Phase 3 development.

Dr. Goeken's Clinical and Regulatory Background at Lobe Sciences

Dr. Goeken's career spans senior roles at Linical, Somahlution, Nuron Biotech, and Pharm-Olam International. The release states he has contributed to regulatory approvals across both FDA and EMA jurisdictions and led successful FDA Orphan Drug and Fast Track designation efforts. He also secured EMA acceptance of MRI biomarkers as a primary endpoint in a pivotal multiple sclerosis trial. His medical degree was earned at St. Christopher's College of Medicine, with clinical training through Louisiana State University Health Sciences Center.

L-130 and S-100 Programme Advancement Under New Leadership

Lobe's lead neurological candidate, L-130 (Conjugated Psilocin®), is a patented new chemical entity being evaluated for generalized anxiety disorder, designed to deliver psilocin at doses below hallucinogenic levels. The company states it is preparing a U.S. IND application for this programme. Its second candidate, S-100, is an oral lipid formulation for sickle cell disease being advanced toward Phase 3 development. The announcement suggests Dr. Goeken will play a central role in designing and executing clinical studies for both programmes.

Independent Trading Group Engaged for Market-Making Services

Separately, Lobe Sciences announced the engagement of Independent Trading Group (ITG), Inc. to provide market-making services for its common shares, also commencing October 19, 2026. Under the agreement, ITG will receive C$6,000 per month plus applicable taxes, with an initial one-month term that automatically renews unless terminated on 30 days' notice. The company states fees are not contingent on share price or trading volume, no shares or options will be issued as compensation, and the two parties are unrelated and unaffiliated entities.